文献速递角膜与眼表疾病

OC-01(伐尼克兰溶液)鼻喷雾剂对干眼病体征和症状的疗效与安全性:ONSET-2 3期随机试验

Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.
PubMed 文献 · Ophthalmology · 2021-11-10

ONSET-2 3期随机双盲多中心安慰剂对照试验纳入758例干眼病患者,评估OC-01鼻喷雾剂每日两次治疗4周的疗效与安全性。OC-01 0.03 mg和0.06 mg组达到Schirmer试验评分改善≥10 mm的患者比例分别为47.3%和49.2%,均显著高于安慰剂组的27.8%(P<0.0001)。OC-01耐受性良好,多数不良事件为轻度非眼部事件。

要点

  • OC-01 0.03 mg和0.06 mg组达到主要终点比例分别为47.3%和49.2%,显著高于安慰剂组27.8%(P<0.0001)。
  • 第4周Schirmer试验评分较基线变化,OC-01两个剂量组均显著大于安慰剂组(P<0.0001)。
  • 86.5%(654/756)患者报告至少1例治疗中出现的不良事件,多为轻度非眼部事件。

核心结论

  • OC-01鼻喷雾剂耐受性良好,对干眼病体征和症状显示出有临床意义的效应。

研究设计与样本

  • 随机、多中心、双盲、赋形剂对照的3期研究。
  • 纳入758例22岁及以上干眼病患者,随机按1:1:1分为OC-01 0.03 mg组(n=260)、OC-01 0.06 mg组(n=246)和赋形剂对照组(n=252)。
  • 每鼻孔每日两次喷入50 μl,治疗4周(ClinicalTrials.gov标识符NCT04036292)。

主要发现

  • 达到主要终点(第4周Schirmer试验评分改善≥10 mm)的患者比例:OC-01 0.03 mg组47.3%,OC-01 0.06 mg组49.2%,赋形剂组27.8%;两个剂量组与赋形剂组比较P均<0.0001。
  • 第4周Schirmer试验评分较基线变化,OC-01两个剂量组均显著大于赋形剂组(P均<0.0001)。
  • 第4周眼干评分在诊室评估中OC-01较赋形剂改善并显示名义显著性,在受控不良环境舱中测量的眼干评分差异不显著。
  • 总体86.5%(654/756)患者在治疗期间报告至少1例治疗中出现的不良事件,多为轻度、非眼部(打喷嚏、咳嗽、咽喉刺激和给药部位刺激),赋形剂组报告的患者比例低于OC-01治疗组(OC-01 0.03 mg组97.3%,OC-01 0.06 mg组99.2%,赋形剂组57%)。

局限性

  • 在受控不良环境舱中测量的眼干评分差异不显著,诊室评估仅显示名义显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of OC-01 (varenicline solution) nasal spray for treatment of patients with dry eye disease. DESIGN: Randomized, multicenter, double-masked, vehicle-controlled, phase 3 study. PARTICIPANTS: Adults 22 years of age or older with a diagnosis of dry eye disease, artificial tear use, Ocular Surface Disease Index score of 23 or more, and Schirmer test score (STS) of 10 mm or less. Eligibility was not restricted by eye dryness score (EDS). METHODS: Patients (N = 758) were randomized in a 1:1:1 ratio to twice-daily treatment with 50-μl intranasal spray in each nostril of OC-01 0.03 mg (n = 260), OC-01 0.06 mg (n = 246), or vehicle (control; n = 252) for 4 weeks (ClinicalTrials.gov identifier, NCT04036292). MAIN OUTCOME MEASURES: The primary efficacy end point was the percentage of patients achieving a 10-mm improvement or more in STS at week 4. Secondary end points included change from baseline to week 4 in STS and EDS in a controlled adverse environment (CAE) chamber and in the clinic. Treatment-emergent adverse events (TEAEs) were assessed. RESULTS: A statistically significantly greater percentage of patients achieved the primary end point in both OC-01 treatment groups compared with the vehicle group (OC-01 0.03 mg, 47.3%; OC-01 0.06 mg, 49.2%; vehicle, 27.8%; P < 0.0001 for both doses). Change from baseline in STS at week 4 was statistically significantly greater for patients receiving OC-01 than vehicle (P < 0.0001 for both doses). Eye dryness score assessed at week 4 improved with OC-01 treatment compared with vehicle, although the difference was not significant for EDS measured in the CAE chamber and showed (nominal) significance in the clinic. Overall, 86.5% of patients (654/756) reported at least 1 TEAE during the treatment period; most were mild, nonocular (sneezing, cough, throat irritation, and instillation site irritation) and were reported by fewer patients in the vehicle group than in the OC-01 treatment groups (OC-01 0.03 mg, 97.3%; OC-01 0.06 mg, 99.2%; vehicle, 57%). CONCLUSIONS: OC-01 nasal spray was well tolerated and showed a clinically meaningful effect on signs and symptoms of dry eye disease.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Wirta D, Vollmer P, Paauw J, et al. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial. Ophthalmology. 2021. PMID: 34767866. doi:10.1016/j.ophtha.2021.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。